Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Bay­er has shut­tered a Phase II pro­gram that the EMA had des­ig­nat­ed an or­phan drug “for sci­en­tif­ic rea­sons,” the Ger­man con­glom­er­ate dis­closed in its half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER